Healthpeak Properties, Inc.
20.39USD
-0.1200 (-0.59%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.03▲ | $0 | 0 | 0 |
| Next quarter | $0.03▲ | $0 | 0 | 0 |
| Current year | $0.09▼ | $0.15 | 0 | 1 |
| Next year | $0.14▼ | $0.15 | 0 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.03 | $0.08 | +0.05 (+198.6%) |
| 2026-03-31 | $0.06 | $0.28 | +0.22 (+364.7%) |
| 2025-12-31 | $0.06 | $0.1 | +0.04 (+59.3%) |
| 2025-09-30 | $0.06 | $-0.18 | -0.24 (-403.2%) |
120 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Equal-Weight | $23 $24 | Aug 31, 2026 |
| Baird | Maintained | Outperform | $21 $24 | Aug 13, 2026 |
| Citigroup | Maintained | Neutral | $20 $22 | Aug 11, 2026 |
| RBC Capital | Maintained | Outperform | $21 $24 | Aug 10, 2026 |
| Cantor Fitzgerald | Maintained | Neutral | $20 $23 | Aug 6, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $20 $22 | Jul 15, 2026 |
| UBS | Maintained | Neutral | $19 $21.5 | Jul 8, 2026 |
| Barclays | Initiated from Overweight | Equal-Weight | $23 | Jul 7, 2026 |
| Mizuho | Maintained | Outperform | $21 $24 | Jul 6, 2026 |
| JP Morgan | Maintained | Neutral | $18 $21 | Jun 24, 2026 |
| BMO Capital | Maintained | Outperform | $20 $24 | Jun 15, 2026 |
| Morgan Stanley | Downgraded from Overweight | Equal-Weight | $20 $22 | Jun 11, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $18 $20 | Jun 1, 2026 |
| Scotiabank | Maintained | Sector Perform | $19 $21 | May 27, 2026 |
| Morgan Stanley | Maintained | Overweight | $18 $20 | May 22, 2026 |
| RBC Capital | Maintained | Outperform | $20 $21 | May 14, 2026 |
| UBS | Maintained | Neutral | $17 $19 | May 13, 2026 |
| Baird | Maintained | Outperform | $19 $21 | May 13, 2026 |
| Citigroup | Maintained | Neutral | $17.5 $20 | May 12, 2026 |
| Morgan Stanley | Maintained | Overweight | $21 $18 | Apr 28, 2026 |
| UBS | Initiated | Neutral | $17 | Apr 20, 2026 |
| Baird | Maintained | Outperform | $20 $19 | Apr 6, 2026 |
| Citigroup | Maintained | Neutral | $18 $17.5 | Apr 1, 2026 |
| Argus Research | Downgraded from Buy | Hold | — | Feb 5, 2026 |
| Evercore ISI Group | Maintained | Outperform | $21 $19 | Feb 4, 2026 |
50 filings from 18 insiders · 13 buy / 1 sell over 6m
Officers and directors of DOC, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| JOHNSTON SHAWN GOfficer | Grant | 1.4k | $15.46 | $21k | May 29, 2026 |
| BRINKER SCOTT MChief Executive Officer | Grant | 1.3k | $15.46 | $21k | May 29, 2026 |
| THOMAS JOHN TDirector | Grant | 1.4k | $15.46 | $21k | May 29, 2026 |
| MOSES KELVIN OChief Financial Officer | Grant | 937 | $15.46 | $14k | May 29, 2026 |
| PATADIA ANKIT BOfficer and Treasurer | Grant | 1.4k | $15.46 | $21k | May 29, 2026 |
| MABRY ADAM GChief Investment Officer | Grant | 625 | $15.46 | $10k | May 29, 2026 |
| BOHN SCOTT ROfficer | Sell | 11.0k | $19.45 | $214k | May 12, 2026 |
| GRIFFIN R KENT JRDirector | Grant | 9.7k | — | — | May 6, 2026 |
| CONNOR JAMES BDirector | Grant | 9.7k | — | — | May 6, 2026 |
| SANDSTROM KATHERINE MDirector | Grant | 9.7k | — | — | May 6, 2026 |
| WEISS RICHARD ADirector | Grant | 9.7k | — | — | May 6, 2026 |
| CARTWRIGHT BRIAN G.Director | Grant | 9.7k | — | — | May 6, 2026 |
| LIAS-BOOKER AVA E.Director | Grant | 9.7k | — | — | May 6, 2026 |
| LEWIS SARA GROOTWASSINKDirector | Grant | 9.7k | — | — | May 6, 2026 |
| THOMAS JOHN TDirector | Grant | 23.7k | — | — | Feb 6, 2026 |
| ALONSO LISA AOfficer | Grant | 4.3k | — | — | Jan 28, 2026 |
| JOHNSTON SHAWN GOfficer | Grant | 1.7k | $14.80 | $25k | Nov 28, 2025 |
| BRINKER SCOTT MChief Executive Officer | Grant | 1.7k | $14.80 | $25k | Nov 28, 2025 |
| THOMAS JOHN TDirector | Grant | 1.4k | $14.80 | $21k | Nov 28, 2025 |
| MOSES KELVIN OChief Financial Officer | Grant | 810 | $14.80 | $12k | Nov 28, 2025 |
No analyst notes on DOC yet.
Analyst Ratings
19 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 5 | 14 | 0 | 0 | Hold2.50 |
| 1 mo ago | 3 | 5 | 14 | 0 | 0 | Hold2.50 |
| 2 mo ago | 3 | 5 | 14 | 0 | 0 | Hold2.50 |
| 3 mo ago | 3 | 5 | 12 | 0 | 0 | Buy2.45 |